Figure 5
Figure 5. Memory phenotype analysis of MAGE-A2212-220–specific CD8+ T-cell response detected in patient no. UPIN18 after treatment with AZA/VPA. The figure shows flow cytometry plots after magnetic enrichment in which the enriched cells were then costained with antibodies against CCR7, CD45RA, CD27, CD28, and CD57. This enabled a full characterization of T-cell differentiation. The gating strategy used is displayed in fluorescence-activated cell sorter plots (i). Fluorescence-activated cell sorter plot (ii) shows the number of MAGE-A2212-220–specific CD8+ T cells (region P5) that expressed CD137. These cells were then plotted against CCR7 and CD45RA (iii). Cells that were CD45RA−CCR7− (region P6) were further plotted against CD27 and CD28 (iv) and CD27 and CD57 (v). Cells that were CD45RA+CCR7− (region P7) were further plotted against CD27 and CD28 (vi) and CD27 and CD57 (vii).

Memory phenotype analysis of MAGE-A2212-220–specific CD8+ T-cell response detected in patient no. UPIN18 after treatment with AZA/VPA. The figure shows flow cytometry plots after magnetic enrichment in which the enriched cells were then costained with antibodies against CCR7, CD45RA, CD27, CD28, and CD57. This enabled a full characterization of T-cell differentiation. The gating strategy used is displayed in fluorescence-activated cell sorter plots (i). Fluorescence-activated cell sorter plot (ii) shows the number of MAGE-A2212-220–specific CD8+ T cells (region P5) that expressed CD137. These cells were then plotted against CCR7 and CD45RA (iii). Cells that were CD45RACCR7 (region P6) were further plotted against CD27 and CD28 (iv) and CD27 and CD57 (v). Cells that were CD45RA+CCR7 (region P7) were further plotted against CD27 and CD28 (vi) and CD27 and CD57 (vii).

Close Modal

or Create an Account

Close Modal
Close Modal